Search

Qiuming M Chu

from Belmont, MA
Age ~63
Get Report
Also known as:
Qiu M Chu, Chu Qiuming
Phone and address:
199 Channing Rd, Belmont, MA 02478
(617) 489-1068
Related to:
Mengyu Chu, 62Yu Zhu Meng, 79
Connected to:
Alain Chu, 56Alina T Chu, 62Angelo C Chu, 29Bang D Chu, 50Bebe Chu, 44Ben Chu, 49Bernadette M Chu, 80Beverley J Chu, 37Brian M Chu, 45Bruce H Chu, 53

Qiuming Chu Phones & Addresses

  • 199 Channing Rd, Belmont, MA 02478 (617) 489-1068
  • 110 Florence St, Melrose, MA 02176 (781) 662-2312
  • Malden, MA

Work

Position: Professional/Technical

Education

Degree: Graduate or professional degree

Emails

c***[email protected]

Resumes

Resumes

Qiuming Chu Photo 1

Staff Scientist

View page
Location:
199 Channing Rd, Belmont, MA 02478
Industry:
Biotechnology
Work:
Sanofi Genzyme
Staff Scientist
Interests:
Football
Exercise
Home Improvement
Reading
Sports
Fishing
Home Decoration
Watching Sports
Photograph
Collecting Coins
Cooking
Skiing
Cruises
Outdoors
Sewing
Electronics
Crafts
Fitness
Music
Camping
Movies
Collecting
Kids
Diet
Travel
Investing
Traveling
Stamp Collecting
Watching Football
Languages:
Mandarin
Qiuming Chu Photo 2

Qiuming Chu

View page

Publications

Us Patents

Systemic Insulin-Like Growth Factor-1 Therapy Reduces Diabetic Peripheral Neuropathy And Improves Renal Function In Diabetic Nephropathy

View page
US Patent:
20100216709, Aug 26, 2010
Filed:
Oct 30, 2009
Appl. No.:
12/609115
Inventors:
Ronald K. Scheule - Framingham MA, US
Qiuming CHU - Framingham MA, US
Assignee:
GENZYME CORPORATION - Cambridge MA
International Classification:
A61K 38/30
A61P 25/02
A61K 31/7088
US Classification:
514 12, 514 44 R
Abstract:
The present invention provides methods of treatment of patients suffering from the complications of blood sugar disorders: diabetic peripheral neuropathy and diabetic nephropathy by administration of IGF-1 via protein therapy or gene therapy. It relates to methods of treating an individual having a diabetic disorder or a hyperglycemic disorder, comprising administering to the individual an effective amount of a DNA vector expressing IGF-1Eb or IGF-1Ec in vivo or an effective amount of at the IGF-1Eb or IGF-1Ec protein in the early hyperalgesia stage or in patients that have advanced to the hyposensitivity stage. Treatment at the early hyperalgesia stage prevents subsequent hyposensitivity with increases or maintenance of sensory nerve function. IGF-1Eb or IGF-1Ec treatment also increases muscle mass and improves overall mobility, which indicates a treatment-related improvement in motor function. Treatment with IGF-1Eb or IGF-1Ec at the hyposensitivity stage reverses hyposensitivity and improves muscle mass and overall health. Systemic IGF-1 provides a therapeutic modality for treating hyposensitivity associated with DPN. In addition, IGF-1Eb or IGF-1Ec provides a therapeutic modality for treating diabetic nephropathy. IGF-1Eb or IGF-1Ec improves renal function as evidenced by a modulation in serum albumin concentration and a reduction in urine volume and protein levels. IGF-1Eb or IGF-1Ec also reduces diabetic glomerulosclerosis.

Cationic Amphiphile Micellar Complexes

View page
US Patent:
20010048940, Dec 6, 2001
Filed:
Jun 18, 1999
Appl. No.:
09/335689
Inventors:
JENNIFER D. TOUSIGNANT - CAMBRIDGE MA, US
SIMON J. EASTMAN - HUDSON MA, US
EDWARD R. LEE - NATICK MA, US
RONALD K. SCHEULE - HOPKINTON MA, US
SENG H. CHENG - WELLESLEY MA, US
J. NIETUPSKI - MILLBURY MA, US
QIUMING CHU - MELROSE MA, US
JOHN MARSHALL - HOPEDALE MA, US
International Classification:
A61K048/00
A61K009/22
A61K009/127
US Classification:
424/450000, 424/468000, 514/044000, 435/458000
Abstract:
The effective introduction of foreign genes and other biologically active molecules into targeted mammalian cells is a challenge still facing those skilled in the art. Gene therapy, for example, requires successful transfection of target cells in a patient. The present invention relates to novel micellar complexes of cationic amphiphilic compounds that facilitate delivery of biologically active molecules to the targeted cells of a mammal. The novel micellar complexes are comprised of a cationic amphiphile, a biologically active molecule, a derivative of polyethylene glycol (PEG), and optionally, a co-lipid. A further aspect of the invention is the use of targeting agents in any of the methods that effectuate the delivery of biologically active molecules into the cells of mammals. A targeting agent is usually any molecule, peptide sequence, or large protein that preferentially targets or binds to specific mammalian cells.
Control profile
Qiuming M Chu from Belmont, MA, age ~63 Get Report